(Total Views: 494)
Posted On: 04/02/2020 8:57:04 AM
Post# of 154227
Check out Amarex posting about CytoDyn and Leronlimab on its Twitter feed on 3/20/20:
https://twitter.com/AmarexClinical/media
On another note, while it may just be semantics or FDA directive or anything else, as a non-medical professional this morning's short Press Release tells me plenty about what Leronlimab is capable of doing for COVID-19 patients... it's great for the general public (news outfits, patients and the common man interested in treatment for COVID-19 which should be all of us to know there's a drug now that can help and give hope).
Again, I'd like to point out one difference that can make all the difference in this morning's PR. Yesterday's Press Release under 'About Coronavirus Disease 2019' stated at the end of the paragraph:
Today's release does NOT have that one important sentence.
Read More: https://investorshangout.com/post/view?id=572...z6ISYI6p10
https://twitter.com/AmarexClinical/media
On another note, while it may just be semantics or FDA directive or anything else, as a non-medical professional this morning's short Press Release tells me plenty about what Leronlimab is capable of doing for COVID-19 patients... it's great for the general public (news outfits, patients and the common man interested in treatment for COVID-19 which should be all of us to know there's a drug now that can help and give hope).
Again, I'd like to point out one difference that can make all the difference in this morning's PR. Yesterday's Press Release under 'About Coronavirus Disease 2019' stated at the end of the paragraph:
Quote:
At this time, there are minimal treatment options for COVID-19.
Today's release does NOT have that one important sentence.
Read More: https://investorshangout.com/post/view?id=572...z6ISYI6p10
(0)
(0)
